AAPL347.68-0.55 (-0.16%) ▼|ABBV285.80+0.61 (+0.21%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|AAPL347.68-0.55 (-0.16%) ▼|ABBV285.80+0.61 (+0.21%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|
15.7 C
New York
Friday, October 23, 2026

Tag: body

newsFORsourcecompanycontentinformation1releasesmarket

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

D1 Training Named a Top 10 Fitness Franchise in Entrepreneur’s New 2026 Industry Rankings

Athletic-Based Training Brand Earns No. 10 Spot Among the Nation's Leading Fitness Franchises in Entrepreneur's Inaugural Industry-Specific RankingNASHVILLE, Tenn., June 8, 2026 /PRNewswire/ --...

/C O R R E C T I O N — PEET’S COFFEE INC./

In the news release, PEET'S COFFEE LAUNCHES NATIONWIDE SEARCH FOR ITS FIRST-EVER "CHIEF PLAYLIST OFFICER" TO BEAT AMERICA'S 3PM SLUMP, issued 03-Jun-2026 by PEET'S...

AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT

AG1 Pro's advanced formula builds on AG1's clinically-backed formula to include additional research-backed key ingredients, including creatine, that target muscle strength, metabolic resilience, and...

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

Behind CISCE with Jason: Inside a hardcore automobile manufacturer and its supplier network

BEIJING, June 8, 2026 /PRNewswire/ -- This is a report from China.org.cn Video Link: China International Supply Chain Expo, or CISCE, showcases not only...

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBody

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers